Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Lifecore Biomedical is a contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceutical products and sodium hyaluronate (HA) production for medical applications. The company operates a 144,000 sq ft FDA-registered facility in Chaska, Minnesota, serving pharmaceutical and medical device clients with aseptic fill-finish services and fermentation-derived HA for ophthalmic, orthopedic, and aesthetic applications. The stock trades on operational execution, capacity utilization, and client contract wins in the competitive CDMO landscape.
Lifecore generates revenue through long-term supply agreements and project-based contracts with pharmaceutical and medical device companies. The CDMO business model relies on high fixed-cost manufacturing infrastructure with pricing power derived from regulatory barriers (FDA compliance, sterile manufacturing expertise) and switching costs once clients validate processes. HA production benefits from vertical integration in fermentation technology, though pricing faces pressure from lower-cost Asian suppliers. Gross margins of 31% reflect capital-intensive operations with moderate utilization rates; profitability depends heavily on facility loading and operational efficiency.
New CDMO contract announcements and client pipeline visibility, particularly multi-year supply agreements with biotech/pharma clients
Facility capacity utilization rates and manufacturing efficiency metrics (batch success rates, turnaround times)
HA pricing trends and competitive dynamics with Asian suppliers (particularly Chinese fermentation producers)
Regulatory inspection outcomes and FDA compliance status for the Chaska facility
Client product launch success and commercial-stage volume ramps for drugs manufactured at Lifecore
CDMO commoditization risk as manufacturing capacity expands globally, particularly in lower-cost geographies (India, China), compressing pricing power for standard fill-finish services
HA market pricing pressure from Asian fermentation producers with 30-50% cost advantages, threatening margin sustainability in the commodity HA segment
Regulatory risk from FDA inspection findings or quality system deficiencies that could halt production or limit new client onboarding
Competition from larger, better-capitalized CDMOs (Catalent, Patheon/Thermo Fisher, Lonza) with broader service offerings and global footprints that can bundle services and offer volume discounts
Client vertical integration risk as larger pharmaceutical companies bring manufacturing in-house to control supply chains and reduce costs
Limited differentiation in sterile fill-finish services beyond regulatory compliance and quality track record
High leverage (Debt/Equity 3.74) combined with negative cash flow creates refinancing risk and limits financial flexibility for growth investments or operational challenges
Negative ROE (-232.8%) and ROA (-15.0%) indicate capital destruction; continued losses erode equity cushion and increase bankruptcy risk if turnaround fails
Working capital strain from inventory requirements and client payment terms could necessitate additional financing at unfavorable terms
low-to-moderate - Pharmaceutical manufacturing demand is relatively recession-resistant as drug development and production continue through economic cycles. However, biotech funding conditions affect client pipeline, and elective medical procedures (orthopedic injections, aesthetic treatments using HA) show modest sensitivity to consumer discretionary spending. The company's negative margins create vulnerability to prolonged downturns that could constrain client capital allocation.
Rising interest rates negatively impact Lifecore through multiple channels: (1) higher financing costs on the company's substantial debt load (Debt/Equity of 3.74), pressuring already-negative cash flow; (2) reduced biotech/pharma client funding as venture capital and IPO markets tighten, potentially delaying CDMO projects; (3) lower valuation multiples for unprofitable growth companies. The 2-year Treasury yield directly affects refinancing risk and working capital costs.
High credit exposure given negative cash flow and elevated leverage. Tightening credit conditions (widening high-yield spreads) increase refinancing risk and could constrain growth capital for facility upgrades or capacity expansion. Client creditworthiness also matters, as biotech bankruptcies could result in contract cancellations or payment delays.
value/turnaround - The stock appeals to distressed/special situations investors betting on operational turnaround, capacity utilization improvement, and margin expansion from current depressed levels. Small-cap healthcare specialists may see CDMO consolidation potential or niche positioning value. Not suitable for income investors (no dividend) or risk-averse growth investors given negative profitability and execution risk.
high - Small-cap ($300M market cap) with negative earnings, high leverage, and illiquid trading creates significant volatility. Stock likely exhibits beta >1.5 to healthcare indices, with sharp moves on contract announcements, earnings surprises, or sector sentiment shifts. Vulnerable to biotech sector volatility and small-cap risk-off periods.
